Online citations, reference lists, and bibliographies.
← Back to Search

Changes In Lung Function After Surgery For Mesothelioma

T. Ploenes, T. Osei-Agyemang, Alexander Krohn, C. F. Waller, V. Duncker-Rohr, M. Elze, B. Passlick
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: The effect of pleurectomy/decortication or extrapleural pleuropneumonectomy on pulmonary function has not yet been evaluated. The aim of this study was to determine the parameters of pulmonary function before and after pleurectomy/decortication or extrapleural pleuropneumonectomy. Methods: We conducted a review of 48 patients with unilateral malignant pleural mesothelioma who underwent pleurectomy/decortication or extrapleural pleuropneumonectomy. Data including medical history, histology, survival, and pre- and postoperative pulmonary function were extracted from the medical database of the University Medical Center Freiburg, or sought by telephone interview with the general practitioner or patients. Results: 25 patients underwent extrapleural pleuropneumonectomy and 23 had pleurectomy/decortication. Pulmonary function was not significantly reduced in the pleurectomy/decortication group postoperatively. In the extrapleural pleuropneumonectomy group, the median preoperative total lung capacity of 4.8 L (77.7%) differed significantly from the postoperative total lung capacity of 3.5 L (55.3%; p < 0.0006). The median vital capacity was significantly reduced from 2.8 L (77.7%) preoperatively to 1.8 L (47.6%) postoperatively (p < 0.0002). Other parameters were also highly significantly reduced after extrapleural pleuropneumonectomy. Conclusions: Pleurectomy/decortication preserved good pulmonary function, whereas extrapleural pleuropneumonectomy significantly reduced pulmonary function, which may lead to dyspnea and influence the quality of life of these patients.
This paper references
10.1510/icvts.2008.181099
Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma.
S. Neragi-Miandoab (2008)
10.1080/14774003.2005.11667666
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
Tim J. Carter (2005)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1378/chest.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1183/09031936.05.00034805
Standardisation of spirometry
M. Miller (2005)
10.1378/CHEST.116.SUPPL_3.446S
Surgical treatment of mesothelioma: pleurectomy.
J. Roberts (1999)
10.1016/S1010-7940(01)01167-8
Decortication in chronic pleural empyema - effect on lung function.
W. Rzyman (2002)
10.1097/JTO.0b013e318201884b
Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non-small Cell Lung Cancer
J. Lee (2011)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1002/JSO.1143
Survival after conservative (palliative) management of pleural malignant mesothelioma
N. Merritt (2001)
10.1002/(SICI)1097-0142(19960915)78:6<1314::AID-CNCR21>3.0.CO;2-2
Dyspnea in cancer patients: Etiology, resource utilization, and survival‐Implications in a managed care world
C. Escalante (1996)
Dyspnea in
CP Escalante
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1510/icvts.2010.256289
Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?
S. Sharif (2011)
10.1016/j.lungcan.2008.01.013
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
K. Ribi (2008)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1183/09031936.05.00035005
Standardisation of the measurement of lung volumes
J. Wanger (2005)
10.1183/09031936.05.00035205
Interpretative strategies for lung function tests
R. Pellegrino (2005)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1136/oem.45.3.182
Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death.
J. Ribak (1988)
10.1016/j.hlc.2010.11.045
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2011)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1016/j.acra.2010.10.009
Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication.
W. Sensakovic (2011)



This paper is referenced by
10.3892/ol.2019.9979
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.
Yuichiro Kai (2019)
10.12788/jcso.0309
Quality of life after surgery for pleural malignant mesothelioma – methodological considerations
Emanuela Taioli (2016)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.13032/TJOP.2052-5931.100120
The Role of Surgery in Malignant Pleural Mesothelioma
Levon Toufektzian (2015)
10.1016/j.jtcvs.2017.10.070
Diaphragm and lung–preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10‐year experience
M. Ambrogi (2018)
10.1245/s10434-018-6458-x
Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification
T. Takuwa (2018)
10.1055/s-0034-1365025
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
10.1007/s00520-017-3666-z
Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma
T. Tanaka (2017)
10.21037/jtd.2018.01.171
Treatment of malignant pleural mesothelioma: lessons learned and quo vadis?
S. Boeluekbas (2018)
10.1007/978-3-319-96244-3_1
History of Pleural Surgical Treatment
Dharmaraj Chauhan (2019)
10.26663/cts.2019.00123
Sustained preservation of pulmonary function after pleurectomy/ decortication: should it be the main reason to perform surgery in malignant pleural mesothelioma patients?
S. Ozer (2019)
10.1007/s12253-016-0181-3
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis
T. Plönes (2016)
10.1007/s10147-015-0925-1
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
S. Hasegawa (2015)
10.1016/j.lungcan.2014.01.021
Surgery for malignant pleural mesothelioma: why, when and what?
L. Lang-Lazdunski (2014)
10.1007/s00595-015-1275-3
Current surgical strategies for malignant pleural mesothelioma
T. Takuwa (2015)
10.1186/s12885-018-5064-4
Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma
R. Schwartz (2018)
10.1186/1756-0500-7-549
Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study
T. Ploenes (2013)
10.2147/NRR.S44751
Pleural mesothelioma: management updates and nursing initiatives to improve patient care
Rebecca H Lehto (2014)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1002/jso.25260
Short‐term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma
M. V. van Gerwen (2018)
10.3390/jcm9072153
Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
Y. Ichiki (2020)
10.1016/j.athoracsur.2015.01.058
Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma.
D. Burkholder (2015)
10.1136/thoraxjnl-2013-203846
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position
A. Datta (2013)
Semantic Scholar Logo Some data provided by SemanticScholar